Tumor cells gain survival advantages through clonal evolution and immune evasion mechanisms. Traditional therapies are evolving to include immune treatments like CAR-T therapy, which shows promise in targeting solid tumors. Advances in CAR-T technology enhance T cell efficacy, leading to improved patient outcomes in cancers like gastric and esophageal cancer.